Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Clindamycin
Drug ID BADD_D00483
Description Clindamycin is a semi-synthetic lincosamide antibiotic used in the treatment of a variety of serious infections due to susceptible microorganisms[L11599,L11596] as well as topically for acne vulgaris.[L11593] It has a relatively narrow spectrum of activity that includes anaerobic bacteria as well as gram-positive cocci and bacilli and gram-negative bacilli.[A190621] Interestingly, clindamycin appears to carry some activity against protozoans, and has been used off-label in the treatment of toxoplasmosis, malaria, and babesiosis.[A190657] Clindamycin is derived from, and has largely replaced, [lincomycin], a naturally occurring lincosamide and the eponymous member of this antibiotic class, due to its improved properties over the parent compound. The name lincomycin is derived from Lincoln, Nebraska, where it was first isolated from _Streptomyces lincolnensis_ found in a soil sample.[A190621]
Indications and Usage In oral and parenteral formulations, clindamycin is indicated for the treatment of serious infections caused by susceptible anaerobic bacteria, as well as susceptible staphylococci, streptococci, and pneumococci.[L11599,L11602] Used topically, it is indicated for the treatment of acne vulgaris[L11593,L11611,L11605] and is available in combination with [benzoyl peroxide][L11584] or [tretinoin][L11590] for this purpose. Clindamycin is also indicated as a vaginal cream[L11596], suppository[L11608], or gel[L39416] for the treatment of bacterial vaginosis in non-pregnant females. Clindamycin is used for antimicrobial prophylaxis against _Viridans_ group streptococcal infections in susceptible patients undergoing oral, dental, or upper respiratory surgery, and may be used for prophylaxis against bacterial endocarditis in penicillin-allergic patients at high risk of these infections.[L11629]
Marketing Status approved; vet_approved
ATC Code D10AF01; G01AA10; J01FF01
DrugBank ID DB01190
KEGG ID D00277
MeSH ID D002981
PubChem ID 2786
TTD Drug ID D0R0ZL
NDC Product Code 67457-816; 71872-7168; 67457-817; 67457-815; 67457-814; 16781-462
UNII 3U02EL437C
Synonyms Clindamycin | Chlolincocin | 7-Chloro-7-deoxylincomycin | 7 Chloro 7 deoxylincomycin | Chlorlincocin | Dalacin C | Clindamycin Monohydrochloride | Monohydrochloride, Clindamycin | Clindamycin Monohydrochloride, Monohydrate | Monohydrate Clindamycin Monohydrochloride | Monohydrochloride, Monohydrate Clindamycin | Cleocin | Clindamycin Hydrochloride | Hydrochloride, Clindamycin
Chemical Information
Molecular Formula C18H33ClN2O5S
CAS Registry Number 18323-44-9
SMILES CCCC1CC(N(C1)C)C(=O)NC(C2C(C(C(C(O2)SC)O)O)O)C(C)Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.0010.000254%Not Available
Abdominal distension07.01.04.001--
Abdominal pain07.01.05.0020.000284%
Abdominal pain upper07.01.05.003--
Abnormal labour18.07.02.001--Not Available
Abortion spontaneous18.01.04.0010.000060%Not Available
Abscess11.01.08.001--Not Available
Abscess sterile08.01.05.008--Not Available
Acne23.02.01.001--Not Available
Agranulocytosis01.02.03.001--Not Available
Anaemia01.03.02.001--
Anaphylactic reaction24.06.03.006; 10.01.07.0010.000134%
Anaphylactic shock24.06.02.004; 10.01.07.002--Not Available
Anaphylactoid reaction24.06.03.007; 10.01.07.003--Not Available
Angioedema22.04.02.008; 23.04.01.001; 10.01.05.0090.000030%Not Available
Application site erythema23.03.06.005; 12.07.01.001; 08.02.01.001--Not Available
Application site pain12.07.01.004; 08.02.01.004--Not Available
Application site pruritus12.07.01.005; 08.02.01.005; 23.03.12.004--Not Available
Application site rash23.03.13.008; 12.07.01.016; 08.02.01.016--Not Available
Application site reaction12.07.01.006; 08.02.01.006--Not Available
Arthralgia15.01.02.0010.000131%
Asthenia08.01.01.0010.000096%Not Available
Azotaemia20.01.01.001--Not Available
Back pain15.03.04.005--
Blister23.03.01.001; 12.01.06.002--Not Available
Body temperature increased13.15.01.001--Not Available
Breath odour07.01.06.002--Not Available
Burning sensation08.01.09.029; 17.02.06.001--Not Available
Cardiac arrest02.03.04.001--
Cardiac failure02.05.01.001--
The 1th Page    1 2 3 4 5    Next   Last    Total 9 Pages